NEW YORK (GenomeWeb) – French companion diagnostics firm ImmunID announced today that it has signed a deal with Memorial Sloan Kettering Cancer Center (MSKCC) to clinically validate its ImmunTracker assay as a predictor of patient response to cancer immunotherapy.

ImmunTracker is a PCR-based system that detects gene recombinations in T cells, providing data about how a cancer patient's immune system is responding to a particular immunotherapy. In collaboration with MSKCC, ImmunID aims to test the assay in solid tumor patients being treated with immune checkpoint inhibitors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.

Sponsored by

This webinar is the last in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.